Ridofranz/iStock via Getty Images2seventy bio, Inc. (NASDAQ:TSVT) is a biotechnology company that develops and distributes Abecma (idecabtagene vicleucel). This is an FDA-approved CAR T cell therapy for multiple myeloma [MM], targeting the B-cell maturation antigen [BCMA]. Abecma has significantly advanced MM treatment and received an FDA extension for relapsed and refractory cases after at least two prior therapies [rrMM]. TSVT seems focused on Abecma now, which has pros and cons. However, I think its ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ For the quarterly period ended March 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ For the transition period from _________ to ________ Commission file number 001-40791 2seventy bio, Inc. (Exact name of registrant as specified in its charter) Delaware 86-3658454 (State or other juri ...

2seventy bio, Inc. (NASDAQ:TSVT) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Jenn Snyder - Senior Vice President, Corporate Affairs Chip Baird - Chief Executive Officer Vicki Eatwell - Chief Financial Officer Anna Truppel-Hartmann - Chief Medical Officer Conference Call Participants Rabib Chaudhury - Leerink Partners Matt Leskowitz - Goldman Sachs Kelsey Goodwin - Guggenheim Securities Morgan Gryga - Morgan Stanley John Newman - Canaccord Genuity Operator Good day and thank ...

2seventy bio Reports First Quarter Financial Results and Recent Operational Progress U.S. FDA Approval of Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy; Commercial Launch Underway Completion of R&D Pipeline Divestiture to Regeneron Sets Company on Track to Focus Exclusively on Development and Commercialization of Abecma with Streamlined Cost Structure Abecma generated $52 million U.S. commercial revenue in the first quarter of 2024 Ended quarter wit ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-40791 2seventy bio, Inc. (Exact name of registrant as specified in its charter) Delaware 86-3658454 (State or other jurisdiction of (I.R. ...

2Seventy Bio, Inc. (NASDAQ:TSVT) Q4 2023 Earnings Conference Call March 5, 2024 8:00 AM ET Company Participants Elizabeth Hickin - Head, IR Chip Baird - Incoming CEO Vicki Eatwell - Incoming CFO Anna Truppel-Hartmann - SVP, Clinical Development Conference Call Participants Daina Graybosch - Leerink Partners Tommie Reerink - Goldman Sachs & Co. Kelsey Goodwin - Guggenheim Securities Samantha Semenkow - Citigroup Operator Good day, and thank you for standing by. Welcome to the 2seventy bio fourth-quarter 2023 ...

2seventy bio, Inc. (NASDAQ:TSVT) Q3 2023 Earnings Call Transcript November 14, 2023 8:00 AM ET Company Participants Elizabeth Hickin - Head of IR Nick Leschly - President and CEO Chip Baird - COO Steve Bernstein - Chief Medical Officer Conference Call Participants Yaron Werber - TD Cowen Kelsey Goodwin - Guggenheim Securities Daina Graybosch - Leerink Partners Samantha Semenkow - Citi John Newman - Canaccord Genuity Operator Good day, and thank you for standing by. Welcome to the 2seventy bio Third Quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ For the quarterly period ended September 30, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ For the transition period from _________ to ________ Commission file number 001-40791 2seventy bio, Inc. (Exact name of registrant as specified in its charter) Delaware 86-3658454 (State or other ...

Unleash Time 2seventy bio company presentation July 2023 Cautionary note regarding forward-looking statements These slides and the accompanying oral presentation may contain “forward-looking statements”. These statements include, but are not limited to: statements about our plans, strategies, timelines and expectations with respect to the development, manufacture or sale of our product candidates, including the design,initiation, enrollment and completion of pre-clinical and clinical studies; timelines for ...

2seventy bio, Inc. (NASDAQ:TSVT) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants Jenn Snyder - SVP of Corporate Affairs Nick Leschly - President and Chief Executive Officer Philip Gregory - Chief Scientific Officer Steven Bernstein - Chief Medical Officer William Baird - Chief Financial Officer Conference Call Participants Daina Graybosch - Leerink Partners Yaron Werber - TD Cowen Kelsey Goodwin - Guggenheim Vikram Purohit - Morgan Stanley Daina Graybosch - Leerink Partners ...